Teradyne heads into the week carrying an unusual tension: a brutal earnings reaction followed by a sharp bounce, with analysts moving fast in both directions in its wake.
The stock dropped 23.8% on April 29 after the Q1 report — its worst single-session earnings reaction on record in this dataset. It then clawed back 5.8% in a single session on May 5, closing at $357.10. The one-week reading is still down 6.1%, and the one-month gain of 15.3% largely reflects the pre-earnings run-up rather than a clean recovery. The next earnings date is July 29, giving the market roughly twelve weeks to reprice expectations from scratch.
The Street moved quickly after the print. JP Morgan's Samik Chatterjee upgraded to Overweight on April 30, keeping a $400 target — a notable signal from a bellwether firm that the flush was overdone. Citi raised its target from $325 to $400 while holding its Buy. Goldman raised from $300 to $350 with a Buy intact. Evercore ISI, however, cut from $430 to $370 after initially raising ahead of the print. The net message is mixed: most buyers are staying in, but consensus remains anchored at Hold with six of seven analysts there, and the mean price target of ~$370 is only marginally above the current price. Return potential ranks at just 3.5% — slim cushion for a name with this level of near-term volatility.
The bull case rests on AI. Semiconductor test revenue from AI applications is expected to top 50% of the mix, with HDD testing potentially doubling by 2026 and mobile/NAND markets offering further lift. The bear case is harder to dismiss after the recent miss: smartphone and datacenter demand remaining weak, share losses at key customers, and US-China trade tensions are all live risks. The robotics/automation segment adds further execution uncertainty. EPS momentum scores are constructive — 85th percentile on 30-day and 71st on 90-day — but the forward P/E of 44.8x and EV/EBITDA of 33.6x leave little room for disappointment.
Short interest tells a secondary story here, not a leading one. At 3.4% of free float, with only 1.1% of available shares currently lent out, the lending market is essentially wide open — far from the 52-week peak availability tightness. Cost to borrow at 0.43% is up about 56% week-on-week, but the absolute level remains trivially low. Short interest has edged up 4.1% over the week and roughly 3.2% over the month, consistent with incremental rebuilding after the earnings drop rather than an aggressive short thesis. The ORTEX short score of 32 puts TER in the 63rd percentile on short score rank — moderately elevated but nowhere near squeeze territory.
Options positioning has nudged more cautious. The put/call ratio is running at 0.675, about 1.2 standard deviations above its 20-day average of 0.628. That's a mild defensive lean, not a panic read — the PCR remains well within its 52-week range — and it sits alongside a RSI14 of 51.5, which describes a stock trying to find footing rather than one being aggressively bid or sold. Close peers AMAT and LRCX both gained around 7-10% on the week, outpacing TER's recovery; UCTT surged 13.7% in a single session. The sector clearly bounced, but TER underperformed its own peer group.
The next focal point is the July 29 earnings call, where the market will test whether AI-driven test demand is durable enough to justify a P/E above 40x after a quarter that shook confidence sharply.
See the live data behind this article on ORTEX.
Open TER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
